IceCure Medical announces annual and special shareholder meeting

• IceCure Medical will hold its annual and special shareholder meeting via remote communication on Nov. 2, 2026.
• Shareholders will vote on reappointing Deloitte Israel as independent auditor, with the board setting remuneration until the next annual meeting.
• A proposal seeks to reappoint director Yang Huang for a three-year term through the 2029 annual meeting.
• Votes are also scheduled on equity awards of 404,901 RSUs to CEO Eyal Shamir, 230,577 RSUs to chairman Ron Mayron.
• Another item covers a 60,000-RSU grant to director Yang Huang, contingent on his reappointment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-104035), on September 28, 2026, and is solely responsible for the information contained therein.